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1. Introduction 
DNA-binding proteins are known to be present in 
human serum and some have been described [ 1,2] . 
Their biological significance is unknown and the 
relationship between serum and intra-nuclear DNA- 
binding proteins is obscure although the latter may be 
related to the control of gene expression. The appear- 
ance of carcinofetal antigens such as CEA [3] , alpha- 
fetoprotein [4] and the DNA-binding protein C3DP 
[2] in malignant disease may indeed be the result of 
derepression of the original foetal genome. A unique 
36 000 dalton DNA-binding protein in foetal cord 
and malignant disease serum has been reported [5] . 
This prompted us to investigate the profile of DNA- 
binding proteins in normal subjects, foetal cord sera 
as well as sera from malignant and non-malignant 
diseases. 
This report describes the presence of a 45 000 
dalton DNA-binding protein which is present in 
normal adult serum but absent from foetal cord and 
the majority of malignant disease sera examined. 
2. Materials and methods 
Serum was obtained from patients having a variety 
of known malignant and non-malignant diseases. 
Normal and foetal cord serum was obtained from 
clinically well subjects. 
DNA-cellulose was prepared as in [6] . Mono- 
specific antiserum to human serum proteins were 
obtained from Behringwerke A. G. and Dakopatts. 
Protein determinations were performed by the 
Lowry method [7] . Dodecyl sulphate disc-gel electro- 
phoresis was carried out in 7% polyacrylamide gels 
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[8] . Molecular weight standards were IgG (155 000), 
bovine serum albumin (68 000), aldolase (40 000), 
pepsin (35 000) carbonic anhydrase (29 000) trypsin 
(22 500) and haemoglobin (16 000). 
Briefly, serum (0.5 ml) was chromatographed on 
mini-columns (0.5 X 6 cm) with 10 mM phosphate 
buffer, pH 6.6. After partial immunoglobulin removal 
the bound material was eluted using the same buffer 
containing 0.5 M NaCl. This eluate was extensively 
dialysed against 10 mM phosphate buffer, pH 6.6, 
containing 1 mM EDTA prior to DNA-cellulose 
chromatography, (1 g protein/100 mg DNA). All 
unbound material was removed and the DNA-bound 
fraction totally eluted with 10 mM phosphate buffer 
containing 0.4 M NaCl. Following dialysis against 
distilled water and protein determination, 60 pg 
lyophilised material was subjected to SDS-poly- 
acrylamide gel electrophoresis after reduction with 
mercaptoethanol. 
3. Results 
The serum DNA-binding protein profiles from 
foetal cord and normal adult are shown in fig.1. The 
most interesting difference was the presence of a 
45 000 dalton DNA-binding protein in normal adult 
serum but apparently absent in the foetal cord fractions. 
A similar molecular weight DNA-binding protein is 
seemingly absent in many cancer patients’ serum but 
present in the majority of non-malignant disease sera 
examined, fig.2 and fig.3 respectively. The complete 
results are shown in table 1. Overall, 60% of the 
44 cases of malignant disease sera studied displayed 
the foetal cord characteristic with the absence of a 
45 000 dalton DNA-binding protein. On the other 
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Fig.1. SDS-polyacrylamide gels of DNA-binding proteins 
from foetal cord (l-3) and normal adult serum (4-6). The 
molecular weights of various proteins are shown. 
Fig.2. SDS-polyacrylamide gels of serum DNA-binding 
proteins from normal adult (l), foetal cord (2) and malig- 
nant disease. Serum from carcinomas of prostate, pancreas, 
colon and lung denoted by 3,4,5 and 6, respectively. The 
colonic carcinoma patient (5) shows an indistinct 45 000 
dalton band. 
Fig.3. SDS-polyacrylamide gels of serum DNA-binding 
proteins from foetal cord (l), normal adult (2) and non- 
malignant disease. Samples 3,4,5 and 6 denote serum from 
psoriasis, dermatitis, bronchitis and rheumatoid arthritis 
patients, respectively. 
hand only 20% of the 30 cases of non-malignant disease 
seia displayed the absence of this protein. Immuno- 
diffusion against both pooled normal and pooled 
foetal cord serum DNA-binding protein preparations 
(1 mg/ml) revealed immunoreactivity towards albumin, 
cu-1-antichymotrypsin, a-2-macroglobulin, C3 com- 
plement and IgG. Additional immunoreactivity 
towards immunoglobulins A and M were present in 
the normal adult DNA-binding fraction. 
4. Discussion 
This paper reports for the first time the observa- 
tion of a serum DNA-binding protein of mol. wt 
45 000 present in normal adults but apparently 
absent in both foetal cord and the majority of malig- 
nant disease sera examined. Parsons et al. [9] have 
described a lower molecular weight malignancy 
associated DNA-binding protein having elevated’levels 
in malignant disease sera. Their 40 000 dalton protein, 
derived from C3 complement, also appears on our 
gels in seemingly elevated amounts in malignant 
disease sera (fig.2). 
Preliminary attempts to identify the 45 000 dalton 
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Table 1 
Absence of a 45 000 dalton DNA-binding protein in serum 
Group No. patients studied No. patients displaying 
absence of 45 000 
dalton protein 
Normal adult 
Foetal cord 
29 - 
20 20 
Malignant disease: 
Carcinoma, primary site 
Breast 
Colon 
Lung 
Prostate 
Others 
Sarcoma 
Lymphoma 
Multiple Myeloma 
4 
9 
3 
4 
13 
3 
5 
3 
Total 44 26 
Non-malignant disease: 
Cirrhosis 
Psoriasis 
Systemic Lupus Erythematosus 
Asthma 
Emphysema 
Others 
4 3 
7 1 
4 - 
3 1 
1 1 
11 - 
Total 30 6 
serum DNA-binding suggest a glycoprotein of o-2 
electrophoretic mobility antigenically similar to 
a-2-HS-glycoprotein. 
It is known that a-2-HS-glycoprotein possesses 
opsonic properties and the ability to alter tumour 
growth [lo] . The relationship of this protein to the 
immunological status of the patient requires further 
investigation. It is tempting to speculate that its 
ability to bind DNA may facilitate the clearance of 
free DNA from the serum which is elevated in 
malignant disease [ 1 l] . 
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